

# Program

## ● Program at a Glance

>> [Friday, 19 May, 2017](#)

>> [Saturday, 20 May, 2017](#)

### Friday, 19 May, 2017

8:30-9:50	<b>Asian Session</b> Current Cell and Gene Therapy in Asia	
10:00-10:40	<b>Special Lecture I</b> Advanced Genetic Engineering of Hematopoiesis to Treat Inherited Diseases	
10:40-11:20	<b>Special Lecture II</b> CAR Therapy: the CD19 paradigm.	
11:30-12:30	<b>Luncheon Seminar</b>	
	<b>Luncheon Seminar 1</b> Co-sponsored by Nippon Shinyaku Co.,Ltd	<b>Luncheon Seminar 2</b> Co-sponsored by Bristol-Myers Squibb K.K.
12:30-13:20	<b>Poster Session</b>	
13:20-15:00	<b>JSH-EHA Joint Session</b> Hematopoietic Stem Cell Gene Therapy for Congenital Disorders	
15:00-15:40	<b>Special lecture III</b> Immunotherapy for Hematologic Malignancies; B Cells and Beyond	
16:00-17:40	<b>Plenary Session I</b> Current Cell and Gene Therapy	
17:40-18:10	Oral Presentation from Poster Presentation	
<b>Reception</b>		

### Saturday, 20 May, 2017

8:00-9:40	<b>Plenary Session II</b> New Horizon of Stem Cell Transplantation	
9:40-10:20	<b>Special lecture IV</b> Gene Therapy for Hemophilia	
10:30-12:10	<b>JSH-ASH Joint Session</b> Next Generation of Cell and Gene Therapy	

Luncheon Seminar

12:20-13:20

**Luncheon Seminar 3**  
Co-sponsored by  
Ono Pharmaceutical Co., Ltd. and  
Bristol-Myers Squibb K.K.

**Luncheon Seminar 4**  
Co-sponsored by Novartis Pharma K.K.

**Program**

[>> Friday, 19 May, 2017](#)

[>> Saturday, 20 May, 2017](#)

**Friday, 19 May, 2017**

**Asian Session Current Cell and Gene Therapy in Asia**

**Current Situation of Cell Therapy in China**

Dr. Kaiyan Liu (Peking University People's Hospital, China)

**T Cell Immunotherapy for EBV-associated Tumor and CMV Reactivation**

Dr. Seok-Goo Cho

(Seoul St. Mary Hospital, College of Medicine, The Catholic University of Korea, Korea)

**Novel Technology of CAR-T Cell Therapy for Treatment of Solid Tumors**

Dr. Koji Tamada (Yamaguchi University Graduate school of Medicine,  
The Institute of Medical Science, The University of Tokyo)

**Haploidentical Allogeneic Stem Cell Transplant in Severe Thalassemia Patients**

Dr. Suradej Hongeng (Ramathibodi Hospital, Mahidol University, Thailand)

8:30-9:50

9:50-10:00

**Break**

**Special Lecture I**

**Advanced Genetic Engineering of Hematopoiesis to Treat Inherited Diseases**

Dr. Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Italy)

10:00-10:40

**Special Lecture II**

**CAR therapy: the CD19 paradigm.**

Dr. Michel Sadelain (Memorial Sloan Kettering Cancer Center, USA)

10:40-11:20

11:20-11:30

**Break**

**Luncheon Seminar 1 (Co-sponsored by Nippon Shinyaku Co.,Ltd.)**

Dr. Raphael Itzykson (Hôpital Saint-Louis, France)

11:30-12:30

**Luncheon Seminar 2 (Co-sponsored by Bristol-Myers Squibb K.K.)**

Dr. Ichiro Hanamura (Aichi Medical University Hospital)

11:30-12:30

12:30-13:20

**Poster Session**

**JSH-EHA Joint Session**

**Hematopoietic Stem Cell Gene Therapy for Congenital Disorders**

**SCID Gene Therapy Including WAS**

Dr. Adrian Thrasher (UCL Great Ormond Street Institute of Child Health, UK)

**Stem Cell Gene Therapy for WAS and Other Disorders**

Dr. Christoph Klein (Hauner Children's Hospital, Ludwig-Maximilian University Munich, Germany)

**Gene Therapy for Immune Deficiency in Japan**

Dr. Masafumi Onodera (Department of Human Genetics)

**Hematopoietic Cell Therapy for Genetic Disorders with Impaired Immune Systems**

Dr. Tomohiro Morio (Tokyo Medical and Dental University)

13:20-15:00

**Special Lecture III**

**Immunotherapy for Hematologic Malignancies; B Cells and Beyond**

Dr. Malcolm Brenner (Center for Cell and Gene Therapy, Baylor College of Medicine, USA)

15:00-15:40

15:40-16:00	<b>Break</b>
16:00-17:40	<b>Plenary Session I "Current Cell and Gene Therapy"</b>
	<b>Gene and Cell-based Medicinal Products in the European Union: Experience and Support by the European Medicines Agency and its Committee for Advanced Therapies.</b> Dr. Patrick Celis (CAT Secretariat European Medicines Agency, UK)
	<b>Update on Regulatory Aspect of Regenerative Medical Products in Japan.</b> Dr. Masakazu Hirata (Pharmaceuticals and Medical Devices Agency)
	<b>New Zinc Finger Nuclease Architectures for Precision Genome Engineering in the Development of T-cell and Hematopoietic Stem/Progenitor Cell Therapies</b> Dr. Michael C. Holmes (Sangamo Therapeutics, Inc., USA)
	<b>CTL019 Project in Japan and United States</b> Dr. Christopher Keir (Novartis Oncology, USA)
	<b>Gene Modified T Cell Therapy in Japan</b> Mr. Masanobu Kimura (Takara Bio Inc)
17:40-18:10	<b>Oral Presentation from Poster Presentation</b>
<b>Reception</b>	

**Saturday, 20 May, 2017**

8:00-9:40	<b>Plenary Session II "New Horizon of Stem Cell Transplantation"</b>
	<b>Placenta-derived decidual stromal cells a novel therapy for severe acute graft-versus-host disease</b> Dr. Olle Ringden (Laboratory Medicine, Karolinska Institutet Translational Cell Therapy Research group, Sweden)
	<b>Engineering Immune Cells from Cord Blood</b> Dr. Catherine M. Bollard (Children's National Medical Center, George Washington University, USA)
	<b>New Aspects of Haploidentical Transplantation Targeting Hematological Malignancies</b> Dr. Takanori Teshima (Hokkaido University)
	<b>New Aspects of Cord Blood Transplantation Targeting Hematological Malignancies</b> Dr. Satoshi Takahashi (Institute of Medical Science, The University of Tokyo)
9:40-10:20	<b>Special Lecture IV</b>
	<b>Gene Therapy for Hemophilia</b> Dr. Katherine A.High (Spark Therapeutics, USA)
10:20-10:30	<b>Break</b>
10:30-12:10	<b>JSH-ASH Joint Session Next Generation of Cell and Gene Therapy</b>
	<b>Therapeutic TCR Mimic Monoclonal Antibodies to Intracellular Oncogenic Proteins.</b> Dr. David A. Scheinberg (Memorial Sloan Kettering Cancer Center, USA)
	<b>Advances in CAR T Cell Therapy for Multiple Myeloma</b> Dr. Alfred Garfall (Perelman School of Medicine, University of Pennsylvania, USA)
	<b>Regeneration of T helper-like Cells that Induces Cytotoxic T cell-Mediated Antitumor Immunity</b> Dr. Shin Kaneko (CiRA Kyoto University)
	<b>Systemic and Potent Dendritic Cell (DC) Activation Modulates the Tumor Microenvironment and Shapes the Long-lived Tumor Specific Memory CD8+T Cells</b> Dr. Shin-ichiro Fujii (Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Sciences , RIKEN)
12:10-12:20	<b>Break</b>
12:20-13:20	<b>Luncheon Seminar 3</b> <b>(Co-sponsored by Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.)</b> Dr. Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
12:20-13:20	<b>Luncheon Seminar 4 (Co-sponsored by Novartis Pharma K.K.)</b> Dr. Hiroshi Fujiwara (Ehime University Hospital)